Skip to main content

Together we are beating cancer

Donate now
  • Science & Technology
  • Health & Medicine
  • Charity News

Cancer Grand Challenges gives a record £100m to five cancer research teams

Tim Gunn
by Tim Gunn | News , Analysis

6 March 2024

2 comments 2 comments

A Cancer Grand Challenges-branded graphic reading 'Announcing five new global Cancer Grand Challenges teams'

Cancer Grand Challenges has awarded five research teams up to £20m each in its largest ever funding round. 

The funded teams include researchers from 12 countries. They will now begin the work needed to take on four of the biggest challenges in cancer research.

Two teams are looking to develop new ways of treating solid tumours in children and young people. They will use new drug technologies to target the previously ‘undruggable’ changes that actually drive these cancers.

Another team will work to improve immunotherapy treatments by studying the ways our immune systems recognise cancer. The final two teams have plans to uncover the reasons behind the global rise in bowel cancer in younger adults and understand why cancer outcomes differ depending on people’s ethnicity.

In total, Cancer Grand Challenges, which was co-founded by Cancer Research UK and the National Cancer Institute in the US, has now given 16 teams of world-leading researchers £315m to take on some of cancer’s toughest challenges. 

In previous funding rounds, between one and four research teams were given up to £20m each.  

Cancer is an incredibly complex and at times elusive disease and the work cancer researchers undertake requires great fortitude and determination.

This year’s winning teams and the teams before them take this to the next level. Cancer Grand Challenge scientists think differently about some of the big questions we have about cancer – why is it so hard to develop new drugs for children’s cancer? Why are outcomes different depending on the patient’s race or ethnicity? Why don’t immunotherapies work for everyone? What’s behind the rise of bowel cancer in younger adults?

These are big questions requiring bold, interdisciplinary approaches to answer them and make a real change in the way we understand, prevent and treat cancer.

- Professor Charles Swanton, Cancer Research UK chief clinician and Cancer Grand Challenges scientific committee member

£40m to improve treatment options for children’s and young people’s cancers

Two teams, KOODAC and PROTECT, have been funded to take on the solid tumours in children challenge. They join team NexTGen, who have been working on a similar challenge since 2022. Cancer Grand Challenges have now committed to invest a total of £60m into improving cancer treatments for children and young people. 

Solid tumours in children are often driven by different genetic changes, or mutations, than adult tumours. They start in developing cells, rather than mature ones, so we usually can’t treat them with targeted drugs that work for older people, like cancer growth blockers. In fact, many of the mutated proteins that drive childhood cancers have historically been considered ‘undruggable’.  

So, while targeted drugs have helped improve how we treat many types of adult cancer, children and young people diagnosed with some types of solid tumour today are in a similar position to those diagnosed in the early 1990s.

They’re still primarily treated with chemotherapy and radiotherapy, which kill cancer cells, but can also damage other healthy ones. Even when they work successfully, these treatments can cause severe long term side effects like infertility, or even increase the risk of future cancers.

But things are changing. Scientists have found the mutations that cause childhood cancers, and they’ve studied what exactly they do. Now, with Cancer Grand Challenges funding, KOODAC and PROTECT are in position to drug the undruggable. They’re developing children’s and young people’s cancer treatments that don’t just block the proteins made by mutated cancer cells, but break them down until they can’t function 

That process is so targeted that it has the potential to kill cancer cells without harming healthy ones. As well as helping more children survive cancer, these drugs could also cause far fewer side effects than other treatments.

Professor Yaël Mossé researching cancer in children and young people at Children's Hospital of Philadelphia
Professor Yaël Mossé (centre), co-team lead of KOODAC, at work in her cancer research lab at Children's Hospital of Philadelphia.

KOODAC’s journey started with one young girl’s big idea. Now the team is preparing to change cancer treatment forever.

“This is really the heart and soul of what we do,” says Professor Yaël Mossé, the team’s co-lead. “We get inspired by our patients, we take that motivation into the lab, and then we take what we learn back to the patients.”

Read KOODAC’s full story here.

Understanding our immune systems and cancer

Team MATCHMAKERS will also focus on improving cancer treatments. Their work on immunotherapies will start with a deep study of how the immune system recognises cancer.

To grow and survive, cancers need to evade immune cells called T cells. We have tens of millions of those inside us. Each one is equipped with a receptor that can spot and latch onto a slightly different threat, whether that’s a breast cancer cell or a type of infection. When a T cell finds its dark match, it leads the immune system to attack it.

Most of the time, this is enough to keep us healthy. Cancer is rare because potential cancer cells can’t grow or survive unless they can trick immune cells into thinking they aren’t dangerous. If they manage that, though, the immune system can’t defend against them.

Immunotherapies are designed to stop that happening, retraining T cells to spot hidden cancers so they can lead the immune response needed to deal with the danger. When they work, these treatments can save lives, but they aren’t effective for everyone. It’s likely that’s linked to the fact we don’t know enough about all the ways different T cells in our bodies might see cancers.

So, MATCHMAKERS plan to track and record all the potential ways T cell receptors can identify cancer cells. Working with artificial intelligence programs, they will then use this data to predict which of all the millions of human T cell receptors have the best chance of seeing an individual’s cancer.

Ultimately, that could make it possible for scientists to create T cell receptors that match specific features of different people’s cancers – guidance systems for a new generation of personalised immunotherapies.

Scientist at Oxford Institute for Radiation Oncology

The Cancer News newsletter brings the latest on Cancer Grand Challenges direct to your inbox

Subscribe

Why are bowel cancer cases rising in under-50s?

The other two funded teams, PROSPECT and SAMBAI, will zoom all the way out to look at cancer on a global, as well as a cellular, scale.

PROSPECT will investigate the unexplained rise in bowel (or colorectal) cancer cases in adults under 50. Thanks largely to researchers funded as part of OPTIMISTICC, another Cancer Grand Challenges team, we know how important this is. Each new generation faces a higher risk of developing early-onset bowel cancer. 

The alarming rise of colorectal cancer in young people around the world demands immediate action. Only by pushing the boundaries of our individual fields can we move quickly to identify opportunities for preventive interventions that can benefit younger generations

- Professor Andrew Chan, co-team lead of PROSPECT

To uncover what’s causing this rise, PROSPECT will line up data on life experiences, genetic changes and generational trends. They’ll also use what they find out to develop ways of preventing these cancers, which they plan to test in the US, UK and India. 

Dr Yin Cao and a colleague looking at data about cancer incidence.
Dr Yin Cao (right) from the University of Washington, St Louis, is co-team lead of PROSPECT.

Facing up to cancer inequities

SAMBAI, meanwhile, are taking on the cancer inequities challenge. They’ve been funded to see why different groups of people have different chances of developing and surviving cancer. The team is also expanding Cancer Grand Challenges’ global reach to Africa, with scientists from institutions in Ghana and South Africa, as well as the US and UK. 

Together, SAMBAI will be looking at how our cancer risks and cancer outcomes are shaped by the world we live in and the one within each of us. In the first case, that means gathering data on people’s social circumstances and environments. It will also involve looking closely at people’s genes, and even considering the different ways their tumours and immune cells might interact.  

All of that will come together in an unprecedented resource – the SAMBAI Biobank and Data Repository for Cancer Equity Research – focused on breast, prostate and pancreatic cancer in people of African descent. With data on 40,000 patients, it will provide the basis for understanding why diverse populations are affected by cancer differently.  

More than that, SAMBAI hope to use what they learn to develop cancer prevention and treatment strategies designed to address cancer inequities. That’s vital, as breast, pancreatic and prostate cancers are typically more aggressive and are diagnosed at an earlier age in Black individuals. 

Challenges and change

But this is about more than the individual teams. In the years to come, the SAMBAI Biobank and Data Repository for Cancer Equity Research will enable researchers from around the world to ask and answer some of the most important questions around cancer inequalities.

Similarly, members of Team PROTECT will work with policymakers to find ways to fund more drug development for children’s and young people’s cancers. That would make announcements like this one – of £40m dedicated to helping more children live longer, better lives – far more common.  

The £100m pledged today will fund five world-leading teams through five years of vital work. But they were chosen for more than that. These teams can make a difference – for scientists, doctors, politicians, parents and people with cancer – for generations to come.

Tim

Team KOODAC, co-led by Martin Eilers, University of Würzburg, and Yaël Mossé, Children’s Hospital of Philadelphia, is funded by Cancer Research UK, Institut National Du Cancer and KiKa (Children Cancer Free Foundation).

Team PROTECT, led by Stefan Pfister, The Hopp Children’s Cancer Center Heidelberg, is funded by Cancer Research UK, the National Cancer Institute, the Scientific Foundation of the Spanish Association Against Cancer and KiKa (Children Cancer Free Foundation). 

Team MATCHMAKERS, led by Michael Birnbaum, Massachusetts Institute of Technology, is funded by Cancer Research UK, the National Cancer Institute and the Mark Foundation for Cancer Research.  

Team PROSPECT, co-led by Andrew Chan, Massachusetts General Hospital and Yin Cao, Washington University, St. Louis, is funded by Cancer Research UK, the National Cancer Institute, the Bowelbabe Fund for Cancer Research UK and Institut National Du Cancer through Cancer Grand Challenges. 

Team SAMBAI, led by Melissa Davis, Morehouse School of Medicine (US), is funded by Cancer Research UK and the National Cancer Institute. 

    Comments

  • Hilary Goldstein
    8 March 2024

    Is there any research currently being done into why cancer patients taking oarp inhibitor drugs have low levels of magnesium and potassium? I am receiving weekly magnesium infusions to boost my levels. Will I need to do this for the rest of my life?

  • Vivienne Davidson
    6 March 2024

    I’d like to know more about the work of CR Horizons in the UK. How they fit into this global work CRUK are now undertaking and how UK based research will continue to be supported with money raised in the UK

  • reply
    Amy Warnock
    12 March 2024

    Hi Vivienne,

    CR Horizon’s have their own website where you can read some of their latest news, including their annual review: https://www.cancerresearchhorizons.com/

    Hopefully that’s helpful!

    Best wishes,
    Amy, Cancer Research UK

    Comments

  • Hilary Goldstein
    8 March 2024

    Is there any research currently being done into why cancer patients taking oarp inhibitor drugs have low levels of magnesium and potassium? I am receiving weekly magnesium infusions to boost my levels. Will I need to do this for the rest of my life?

  • Vivienne Davidson
    6 March 2024

    I’d like to know more about the work of CR Horizons in the UK. How they fit into this global work CRUK are now undertaking and how UK based research will continue to be supported with money raised in the UK

  • reply
    Amy Warnock
    12 March 2024

    Hi Vivienne,

    CR Horizon’s have their own website where you can read some of their latest news, including their annual review: https://www.cancerresearchhorizons.com/

    Hopefully that’s helpful!

    Best wishes,
    Amy, Cancer Research UK